{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:45:42Z","timestamp":1788385542634,"version":"build-2803163510"},"publisher-location":"Cham","reference-count":123,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031384363","type":"print"},{"value":"9783031384370","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/164_2022_629","type":"book-chapter","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T07:02:58Z","timestamp":1672642978000},"page":"107-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Role of Striatal Cav1.3 Calcium Channels in Therapeutics for Parkinson\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Margaret E.","family":"Caulfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredric P.","family":"Manfredsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Steece-Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"key":"629_CR1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","volume":"70","author":"XM Anguela","year":"2019","unstructured":"Anguela XM, High KA (2019) Entering the modern era of gene therapy. Annu Rev Med 70:273\u2013288","journal-title":"Annu Rev Med"},{"key":"629_CR2","doi-asserted-by":"crossref","first-page":"10302","DOI":"10.1523\/JNEUROSCI.22-23-10302.2002","volume":"22","author":"M Azzouz","year":"2002","unstructured":"Azzouz M, Martin-Rendon E, Barber RD, Mitrophanous KA, Carter EE, Rohll JB, Kingsman SM, Kingsman AJ, Mazarakis ND (2002) Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 22:10302\u201310312","journal-title":"J Neurosci"},{"key":"629_CR3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2011.05.026","volume":"44","author":"RT Bartus","year":"2011","unstructured":"Bartus RT, Brown L, Wilson A, Kruegel B, Siffert J, Johnson EM Jr, Kordower JH, Herzog CD (2011) Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis 44:38\u201352","journal-title":"Neurobiol Dis"},{"key":"629_CR4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neurobiolaging.2012.07.018","volume":"34","author":"RT Bartus","year":"2013","unstructured":"Bartus RT, Baumann TL, Brown L, Kruegel BR, Ostrove JM, Herzog CD (2013) Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating \u201cclinical proof-of-concept\u201d for AAV-neurturin (CERE-120) in Parkinson's disease. Neurobiol Aging 34:35\u201361","journal-title":"Neurobiol Aging"},{"key":"629_CR5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","volume":"132","author":"MF Bastide","year":"2015","unstructured":"Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, De Deurwaerdere P, Ko WK, Simola N, Morelli M, Groc L, Rodriguez MC, Gurevich EV, Quik M, Morari M, Mellone M, Gardoni F, Tronci E, Guehl D, Tison F, Crossman AR, Kang UJ, Steece-Collier K, Fox S, Carta M, Angela Cenci M, Bezard E (2015) Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Prog Neurobiol 132:96\u2013168","journal-title":"Prog Neurobiol"},{"key":"629_CR6","doi-asserted-by":"crossref","first-page":"14845","DOI":"10.1073\/pnas.1009874107","volume":"107","author":"HS Bateup","year":"2010","unstructured":"Bateup HS, Santini E, Shen W, Birnbaum S, Valjent E, Surmeier DJ, Fisone G, Nestler EJ, Greengard P (2010) Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A 107:14845\u201314850","journal-title":"Proc Natl Acad Sci U S A"},{"key":"629_CR7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00441-014-1936-3","volume":"357","author":"SM Berger","year":"2014","unstructured":"Berger SM, Bartsch D (2014) The role of L-type voltage-gated calcium channels Cav1.2 and Cav1.3 in normal and pathological brain function. Cell Tissue Res 357:463\u2013476","journal-title":"Cell Tissue Res"},{"key":"629_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2012.06.001","volume":"99","author":"S Bhat","year":"2012","unstructured":"Bhat S, Dao DT, Terrillion CE, Arad M, Smith RJ, Soldatov NM, Gould TD (2012) CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog Neurobiol 99:1\u201314","journal-title":"Prog Neurobiol"},{"key":"629_CR9","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41587-020-0642-9","volume":"38","author":"NIB-N Biotech","year":"2020","unstructured":"Biotech NIB-N (2020) High-dose AAV gene therapy deaths. Nat Biotechnol 38:910","journal-title":"Nat Biotechnol"},{"key":"629_CR10","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/mds.25135","volume":"27","author":"JP Bolam","year":"2012","unstructured":"Bolam JP, Pissadaki EK (2012) Living on the edge with too many mouths to feed: why dopamine neurons die. Mov Disord 27:1478\u20131483","journal-title":"Mov Disord"},{"issue":"Pt 4","key":"629_CR11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1046\/j.1469-7580.2000.19640527.x","volume":"196","author":"JP Bolam","year":"2000","unstructured":"Bolam JP, Hanley JJ, Booth PA, Bevan MD (2000) Synaptic organisation of the basal ganglia. J Anat 196(Pt 4):527\u2013542","journal-title":"J Anat"},{"key":"629_CR12","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1038\/s41467-020-19505-2","volume":"11","author":"K Bulaklak","year":"2020","unstructured":"Bulaklak K, Gersbach CA (2020) The once and future gene therapy. Nat Commun 11:5820","journal-title":"Nat Commun"},{"key":"629_CR13","doi-asserted-by":"crossref","unstructured":"Callens M, Loncke J, Bultynck G (2022) Dysregulated Ca(2+) homeostasis as a central theme in neurodegeneration: lessons from Alzheimer's disease and Wolfram syndrome. Cells 11","DOI":"10.3390\/cells11121963"},{"key":"629_CR14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fnmol.2019.00055","volume":"12","author":"C Catoni","year":"2019","unstructured":"Catoni C, Cali T, Brini M (2019) Calcium, dopamine and neuronal calcium sensor 1: their contribution to Parkinson's disease. Front Mol Neurosci 12:55","journal-title":"Front Mol Neurosci"},{"key":"629_CR15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/pr.57.4.4","volume":"57","author":"WA Catterall","year":"2005","unstructured":"Catterall WA, Goldin AL, Waxman SG (2005) International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 57:397\u2013409","journal-title":"Pharmacol Rev"},{"key":"629_CR16","doi-asserted-by":"crossref","first-page":"749722","DOI":"10.3389\/fnhum.2021.749722","volume":"15","author":"T Chen","year":"2021","unstructured":"Chen T, Lin F, Cai G (2021) Comparison of the efficacy of deep brain stimulation in different targets in improving gait in Parkinson's disease: a systematic review and Bayesian network meta-analysis. Front Hum Neurosci 15:749722","journal-title":"Front Hum Neurosci"},{"key":"629_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2010.12.017","volume":"508","author":"SC Daubner","year":"2011","unstructured":"Daubner SC, Le T, Wang S (2011) Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 508:1\u201312","journal-title":"Arch Biochem Biophys"},{"key":"629_CR18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nn1632","volume":"9","author":"M Day","year":"2006","unstructured":"Day M, Wang Z, Ding J, An X, Ingham CA, Shering AF, Wokosin D, Ilijic E, Sun Z, Sampson AR, Mugnaini E, Deutch AY, Sesack SR, Arbuthnott GW, Surmeier DJ (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9:251\u2013259","journal-title":"Nat Neurosci"},{"key":"629_CR19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","volume":"13","author":"MR DeLong","year":"1990","unstructured":"DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281\u2013285","journal-title":"Trends Neurosci"},{"key":"629_CR21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature11860","volume":"493","author":"DH Ebert","year":"2013","unstructured":"Ebert DH, Greenberg ME (2013) Activity-dependent neuronal signalling and autism spectrum disorder. Nature 493:327\u2013337","journal-title":"Nature"},{"key":"629_CR22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/mds.26102","volume":"30","author":"S Fahn","year":"2015","unstructured":"Fahn S (2015) The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord 30:4\u201318","journal-title":"Mov Disord"},{"key":"629_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mds.26122","volume":"30","author":"S Fahn","year":"2015","unstructured":"Fahn S, Poewe W (2015) Levodopa: 50 years of a revolutionary drug for Parkinson disease. Mov Disord 30:1\u20133","journal-title":"Mov Disord"},{"key":"629_CR24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrneurol.2014.252","volume":"11","author":"A Fasano","year":"2015","unstructured":"Fasano A, Aquino CC, Krauss JK, Honey CR, Bloem BR (2015) Axial disability and deep brain stimulation in patients with Parkinson disease. Nat Rev Neurol 11:98\u2013110","journal-title":"Nat Rev Neurol"},{"key":"629_CR25","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mds.26139","volume":"30","author":"T Fieblinger","year":"2015","unstructured":"Fieblinger T, Cenci MA (2015) Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia. Mov Disord 30:484\u2013493","journal-title":"Mov Disord"},{"key":"629_CR26","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1038\/ncomms6316","volume":"5","author":"T Fieblinger","year":"2014","unstructured":"Fieblinger T, Graves SM, Sebel LE, Alcacer C, Plotkin JL, Gertler TS, Chan CS, Heiman M, Greengard P, Cenci MA, Surmeier DJ (2014) Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. Nat Commun 5:5316","journal-title":"Nat Commun"},{"key":"629_CR27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00424-020-02368-3","volume":"472","author":"BE Flucher","year":"2020","unstructured":"Flucher BE (2020) Skeletal muscle CaV1.1 channelopathies. Pflugers Arch 472:739\u2013754","journal-title":"Pflugers Arch"},{"key":"629_CR28","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1152\/jn.00038.2009","volume":"102","author":"RC Foehring","year":"2009","unstructured":"Foehring RC, Zhang XF, Lee JC, Callaway JC (2009) Endogenous calcium buffering capacity of substantia nigral dopamine neurons. J Neurophysiol 102:2326\u20132333","journal-title":"J Neurophysiol"},{"key":"629_CR29","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.3171\/foc.2004.17.1.3","volume":"17","author":"KA Follett","year":"2004","unstructured":"Follett KA (2004) Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesias. Neurosurg Focus 17:E3","journal-title":"Neurosurg Focus"},{"key":"629_CR30","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12640-012-9366-z","volume":"23","author":"J Follett","year":"2013","unstructured":"Follett J, Darlow B, Wong MB, Goodwin J, Pountney DL (2013) Potassium depolarization and raised calcium induces alpha-synuclein aggregates. Neurotox Res 23:378\u2013392","journal-title":"Neurotox Res"},{"key":"629_CR31","doi-asserted-by":"crossref","first-page":"623717","DOI":"10.3389\/fgeed.2020.623717","volume":"2","author":"HR Frederiksen","year":"2020","unstructured":"Frederiksen HR, Doehn U, Tveden-Nyborg P, Freude KK (2020) Non-immunogenic induced pluripotent stem cells, a promising way forward for allogenic transplantations for neurological disorders. Front Genome Ed 2:623717","journal-title":"Front Genome Ed"},{"key":"629_CR32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1471-4159.2006.03803.x","volume":"97","author":"K Furukawa","year":"2006","unstructured":"Furukawa K, Matsuzaki-Kobayashi M, Hasegawa T, Kikuchi A, Sugeno N, Itoyama Y, Wang Y, Yao PJ, Bushlin I, Takeda A (2006) Plasma membrane ion permeability induced by mutant alpha-synuclein contributes to the degeneration of neural cells. J Neurochem 97:1071\u20131077","journal-title":"J Neurochem"},{"key":"629_CR33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nbd.2007.04.003","volume":"27","author":"M Gasmi","year":"2007","unstructured":"Gasmi M, Brandon EP, Herzog CD, Wilson A, Bishop KM, Hofer EK, Cunningham JJ, Printz MA, Kordower JH, Bartus RT (2007) AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis 27:67\u201376","journal-title":"Neurobiol Dis"},{"key":"629_CR34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-neuro-061010-113641","volume":"34","author":"CR Gerfen","year":"2011","unstructured":"Gerfen CR, Surmeier DJ (2011) Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 34:441\u2013466","journal-title":"Annu Rev Neurosci"},{"key":"629_CR35","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1021\/acschemneuro.9b00320","volume":"10","author":"S Ghio","year":"2019","unstructured":"Ghio S, Camilleri A, Caruana M, Ruf VC, Schmidt F, Leonov A, Ryazanov S, Griesinger C, Cauchi RJ, Kamp F, Giese A, Vassallo N (2019) Cardiolipin promotes pore-forming activity of alpha-synuclein oligomers in mitochondrial membranes. ACS Chem Nerosci 10:3815\u20133829","journal-title":"ACS Chem Nerosci"},{"key":"629_CR36","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0959-4388(95)80100-6","volume":"5","author":"AM Graybiel","year":"1995","unstructured":"Graybiel AM (1995) Building action repertoires: memory and learning functions of the basal ganglia. Curr Opin Neurobiol 5:733\u2013741","journal-title":"Curr Opin Neurobiol"},{"key":"629_CR37","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1017\/S0033291715000537","volume":"45","author":"R Gurung","year":"2015","unstructured":"Gurung R, Prata DP (2015) What is the impact of genome-wide supported risk variants for schizophrenia and bipolar disorder on brain structure and function? A systematic review. Psychol Med 45:2461\u20132480","journal-title":"Psychol Med"},{"key":"629_CR38","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nature09536","volume":"468","author":"JN Guzman","year":"2010","unstructured":"Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, Schumacker PT, Surmeier DJ (2010) Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468:696\u2013700","journal-title":"Nature"},{"key":"629_CR39","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3233\/JPD-171134","volume":"7","author":"RA Hauser","year":"2017","unstructured":"Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, Felt L, Stempien MJ (2017) ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 2 Study): interim results of an open-label safety study. J Parkinsons Dis 7:511\u2013522","journal-title":"J Parkinsons Dis"},{"key":"629_CR40","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1083\/jcb.123.4.949","volume":"123","author":"JW Hell","year":"1993","unstructured":"Hell JW, Westenbroek RE, Warner C, Ahlijanian MK, Prystay W, Gilbert MM, Snutch TP, Catterall WA (1993) Identification and differential subcellular localization of the neuronal class C and class D L-type calcium channel alpha 1 subunits. J Cell Biol 123:949\u2013962","journal-title":"J Cell Biol"},{"key":"629_CR41","doi-asserted-by":"crossref","first-page":"8987","DOI":"10.1523\/JNEUROSCI.20-24-08987.2000","volume":"20","author":"S Hernandez-Lopez","year":"2000","unstructured":"Hernandez-Lopez S, Tkatch T, Perez-Garci E, Galarraga E, Bargas J, Hamm H, Surmeier DJ (2000) D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J Neurosci Off J Soc Neurosci 20:8987\u20138995","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"629_CR42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2013.04.011","volume":"58","author":"CD Herzog","year":"2013","unstructured":"Herzog CD, Brown L, Kruegel BR, Wilson A, Tansey MG, Gage FH, Johnson EM Jr, Bartus RT (2013) Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). Neurobiol Dis 58:38\u201348","journal-title":"Neurobiol Dis"},{"key":"629_CR43","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1471-4159.2009.06411.x","volume":"111","author":"NT Hettiarachchi","year":"2009","unstructured":"Hettiarachchi NT, Parker A, Dallas ML, Pennington K, Hung CC, Pearson HA, Boyle JP, Robinson P, Peers C (2009) alpha-Synuclein modulation of Ca2+ signaling in human neuroblastoma (SH-SY5Y) cells. J Neurochem 111:1192\u20131201","journal-title":"J Neurochem"},{"key":"629_CR44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pneurobio.2015.09.002","volume":"134","author":"S Heyes","year":"2015","unstructured":"Heyes S, Pratt WS, Rees E, Dahimene S, Ferron L, Owen MJ, Dolphin AC (2015) Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders. Prog Neurobiol 134:36\u201354","journal-title":"Prog Neurobiol"},{"key":"629_CR45","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/19336950.2020.1859260","volume":"15","author":"NT Hofer","year":"2021","unstructured":"Hofer NT, Pinggera A, Nikonishyna YV, Tuluc P, Fritz EM, Obermair GJ, Striessnig J (2021) Stabilization of negative activation voltages of Cav1.3 L-Type Ca(2+)-channels by alternative splicing. Channels (Austin) 15:38\u201352","journal-title":"Channels (Austin)"},{"key":"629_CR46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","volume":"65","author":"P Huot","year":"2013","unstructured":"Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM (2013) The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev 65:171\u2013222","journal-title":"Pharmacol Rev"},{"key":"629_CR47","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.nbd.2011.04.007","volume":"43","author":"E Ilijic","year":"2011","unstructured":"Ilijic E, Guzman JN, Surmeier DJ (2011) The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis 43:364\u2013371","journal-title":"Neurobiol Dis"},{"key":"629_CR48","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0006-8993(89)91686-7","volume":"503","author":"CA Ingham","year":"1989","unstructured":"Ingham CA, Hood SH, Arbuthnott GW (1989) Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age. Brain Res 503:334\u2013338","journal-title":"Brain Res"},{"key":"629_CR49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF00227776","volume":"93","author":"CA Ingham","year":"1993","unstructured":"Ingham CA, Hood SH, van Maldegem B, Weenink A, Arbuthnott GW (1993) Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. Exp Brain Res 93:17\u201327","journal-title":"Exp Brain Res"},{"key":"629_CR50","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1566523220999200716111502","volume":"20","author":"A Iqubal","year":"2020","unstructured":"Iqubal A, Iqubal MK, Khan A, Ali J, Baboota S, Haque SE (2020) Gene therapy, a novel therapeutic tool for neurological disorders: current progress, challenges and future prospective. Curr Gene Ther 20:184\u2013194","journal-title":"Curr Gene Ther"},{"key":"629_CR51","doi-asserted-by":"crossref","first-page":"2ra4","DOI":"10.1126\/scitranslmed.3000130","volume":"1","author":"B Jarraya","year":"2009","unstructured":"Jarraya B, Boulet S, Ralph GS, Jan C, Bonvento G, Azzouz M, Miskin JE, Shin M, Delzescaux T, Drouot X, Herard AS, Day DM, Brouillet E, Kingsman SM, Hantraye P, Mitrophanous KA, Mazarakis ND, Palfi S (2009) Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 1:2ra4","journal-title":"Sci Transl Med"},{"key":"629_CR52","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.1113\/JP270673","volume":"594","author":"ZD Kabir","year":"2016","unstructured":"Kabir ZD, Lee AS, Rajadhyaksha AM (2016) L-type Ca(2+) channels in mood, cognition and addiction: integrating human and rodent studies with a focus on behavioural endophenotypes. J Physiol 594:5823\u20135837","journal-title":"J Physiol"},{"key":"629_CR53","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s13311-017-0532-0","volume":"14","author":"ZD Kabir","year":"2017","unstructured":"Kabir ZD, Martinez-Rivera A, Rajadhyaksha AM (2017) From gene to behavior: L-type calcium channel mechanisms underlying neuropsychiatric symptoms. Neurotherapeutics 14:588\u2013613","journal-title":"Neurotherapeutics"},{"key":"629_CR54","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/ncomms2149","volume":"3","author":"S Kang","year":"2012","unstructured":"Kang S, Cooper G, Dunne SF, Dusel B, Luan CH, Surmeier DJ, Silverman RB (2012) CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat Commun 3:1146","journal-title":"Nat Commun"},{"key":"629_CR55","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1016\/j.bmc.2013.04.054","volume":"21","author":"S Kang","year":"2013","unstructured":"Kang S, Cooper G, Dunne SF, Luan CH, James Surmeier D, Silverman RB (2013a) Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics. Bioorg Med Chem 21:4365\u20134373","journal-title":"Bioorg Med Chem"},{"key":"629_CR56","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1021\/jm4005048","volume":"56","author":"S Kang","year":"2013","unstructured":"Kang S, Cooper G, Dunne SF, Luan CH, Surmeier DJ, Silverman RB (2013b) Structure-activity relationship of N,N'-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson's disease. J Med Chem 56:4786\u20134797","journal-title":"J Med Chem"},{"key":"629_CR57","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.21032","volume":"60","author":"JH Kordower","year":"2006","unstructured":"Kordower JH, Herzog CD, Dass B, Bakay RA, Stansell J 3rd, Gasmi M, Bartus RT (2006) Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 60:706\u2013715","journal-title":"Ann Neurol"},{"key":"629_CR58","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4161\/chan.4.6.12872","volume":"4","author":"A Koschak","year":"2010","unstructured":"Koschak A (2010) Impact of gating modulation in CaV1.3 L-type calcium channels. Channels (Austin) 4:523\u2013525","journal-title":"Channels (Austin)"},{"key":"629_CR59","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00424-021-02570-x","volume":"473","author":"A Koschak","year":"2021","unstructured":"Koschak A, Fernandez-Quintero ML, Heigl T, Ruzza M, Seitter H, Zanetti L (2021) Cav1.4 dysfunction and congenital stationary night blindness type 2. Pflugers Arch 473:1437\u20131454","journal-title":"Pflugers Arch"},{"key":"629_CR60","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/384467a0","volume":"384","author":"PT Kotzbauer","year":"1996","unstructured":"Kotzbauer PT, Lampe PA, Heuckeroth RO, Golden JP, Creedon DJ, Johnson EM Jr, Milbrandt J (1996) Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384:467\u2013470","journal-title":"Nature"},{"key":"629_CR61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/mds.26120","volume":"30","author":"AJ Lees","year":"2015","unstructured":"Lees AJ, Tolosa E, Olanow CW (2015) Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Mov Disord 30:19\u201336","journal-title":"Mov Disord"},{"key":"629_CR62","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"PA LeWitt","year":"2011","unstructured":"LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A (2011) AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10:309\u2013319","journal-title":"Lancet Neurol"},{"key":"629_CR63","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/009885881003600103","volume":"36","author":"BA Liang","year":"2010","unstructured":"Liang BA, Mackey T (2010) Confronting conflict: addressing institutional conflicts of interest in academic medical centers. Am J Law Med 36:136\u2013187","journal-title":"Am J Law Med"},{"key":"629_CR64","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/mdc3.13379","volume":"9","author":"Z Lin","year":"2022","unstructured":"Lin Z, Zhang C, Li D, Sun B (2022) Preoperative levodopa response and deep brain stimulation effects on motor outcomes in Parkinson's disease: a systematic review. Mov Disord Clin Pract 9:140\u2013155","journal-title":"Mov Disord Clin Pract"},{"key":"629_CR65","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pharmtox-010818-021214","volume":"59","author":"B Liss","year":"2019","unstructured":"Liss B, Striessnig J (2019) The potential of L-type calcium channels as a drug target for neuroprotective therapy in Parkinson's disease. Annu Rev Pharmacol Toxicol 59:263\u2013289","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"629_CR66","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1110\/ps.04879704","volume":"13","author":"R Lowe","year":"2004","unstructured":"Lowe R, Pountney DL, Jensen PH, Gai WP, Voelcker NH (2004) Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci 13:3245\u20133252","journal-title":"Protein Sci"},{"key":"629_CR67","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1523\/JNEUROSCI.17-04-01339.1997","volume":"17","author":"A Ludwig","year":"1997","unstructured":"Ludwig A, Flockerzi V, Hofmann F (1997) Regional expression and cellular localization of the alpha1 and beta subunit of high voltage-activated calcium channels in rat brain. J Neurosci 17:1339\u20131349","journal-title":"J Neurosci"},{"key":"629_CR68","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","volume":"126","author":"AM Maguire","year":"2019","unstructured":"Maguire AM, Russell S, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci O, Marshall KA, McCague S, Reichert H, Davis M, Simonelli F, Leroy BP, Wright JF, High KA, Bennett J (2019) Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology 126:1273\u20131285","journal-title":"Ophthalmology"},{"key":"629_CR69","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M20-1023","volume":"172","author":"B Maiti","year":"2020","unstructured":"Maiti B, Perlmutter JS (2020) A clinical trial of isradipine: what went wrong? Ann Intern Med 172:625\u2013626","journal-title":"Ann Intern Med"},{"key":"629_CR70","doi-asserted-by":"crossref","first-page":"593572","DOI":"10.3389\/fnagi.2020.593572","volume":"12","author":"FP Manfredsson","year":"2020","unstructured":"Manfredsson FP, Polinski NK, Subramanian T, Boulis N, Wakeman DR, Mandel RJ (2020) The future of GDNF in Parkinson's disease. Front Aging Neurosci 12:593572","journal-title":"Front Aging Neurosci"},{"key":"629_CR71","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"WJ Marks Jr","year":"2010","unstructured":"Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Kordower JH, Olanow CW (2010) Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 9:1164\u20131172","journal-title":"Lancet Neurol"},{"key":"629_CR72","doi-asserted-by":"crossref","first-page":"e4770","DOI":"10.1371\/journal.pone.0004770","volume":"4","author":"M Matamales","year":"2009","unstructured":"Matamales M, Bertran-Gonzalez J, Salomon L, Degos B, Deniau JM, Valjent E, Herve D, Girault JA (2009) Striatal medium-sized spiny neurons: identification by nuclear staining and study of neuronal subpopulations in BAC transgenic mice. PLoS One 4:e4770","journal-title":"PLoS One"},{"key":"629_CR73","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0006-8993(88)90124-2","volume":"455","author":"TH McNeill","year":"1988","unstructured":"McNeill TH, Brown SA, Rafols JA, Shoulson I (1988) Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease. Brain Res 455:148\u2013152","journal-title":"Brain Res"},{"key":"629_CR74","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s00702-019-02076-y","volume":"126","author":"JM Mossner","year":"2019","unstructured":"Mossner JM, Patil PG, Chou KL (2019) Subthalamic nucleus deep brain stimulation improves dyskinesias in Parkinson's disease beyond levodopa reduction. J Neural Transm (Vienna) 126:1479\u20131483","journal-title":"J Neural Transm (Vienna)"},{"key":"629_CR75","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0006-8993(94)90511-8","volume":"668","author":"A Mouatt-Prigent","year":"1994","unstructured":"Mouatt-Prigent A, Agid Y, Hirsch EC (1994) Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease? Brain Res 668:62\u201370","journal-title":"Brain Res"},{"key":"629_CR76","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.mcn.2010.12.004","volume":"46","author":"S Nath","year":"2011","unstructured":"Nath S, Goodwin J, Engelborghs Y, Pountney DL (2011) Raised calcium promotes alpha-synuclein aggregate formation. Mol Cell Neurosci 46:516\u2013526","journal-title":"Mol Cell Neurosci"},{"key":"629_CR77","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/mds.25826","volume":"29","author":"H Nishijima","year":"2014","unstructured":"Nishijima H, Suzuki S, Kon T, Funamizu Y, Ueno T, Haga R, Suzuki C, Arai A, Kimura T, Suzuki C, Meguro R, Miki Y, Yamada J, Migita K, Ichinohe N, Ueno S, Baba M, Tomiyama M (2014) Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model. Mov Disord 29:336\u2013343","journal-title":"Mov Disord"},{"key":"629_CR78","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.molmed.2015.06.001","volume":"21","author":"DM O'Connor","year":"2015","unstructured":"O'Connor DM, Boulis NM (2015) Gene therapy for neurodegenerative diseases. Trends Mol Med 21:504\u2013512","journal-title":"Trends Mol Med"},{"key":"629_CR79","doi-asserted-by":"crossref","first-page":"636103","DOI":"10.3389\/fnsyn.2021.636103","volume":"13","author":"NJ Ortner","year":"2021","unstructured":"Ortner NJ (2021) Voltage-gated Ca(2+) channels in dopaminergic substantia nigra neurons: therapeutic targets for neuroprotection in Parkinson's disease? Front Synaptic Neurosci 13:636103","journal-title":"Front Synaptic Neurosci"},{"key":"629_CR80","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/19336950.2015.1048936","volume":"10","author":"NJ Ortner","year":"2016","unstructured":"Ortner NJ, Striessnig J (2016) L-type calcium channels as drug targets in CNS disorders. Channels (Austin) 10:7\u201313","journal-title":"Channels (Austin)"},{"key":"629_CR81","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00424-020-02418-w","volume":"472","author":"NJ Ortner","year":"2020","unstructured":"Ortner NJ, Kaserer T, Copeland JN, Striessnig J (2020) De novo CACNA1D Ca(2+) channelopathies: clinical phenotypes and molecular mechanism. Pflugers Arch 472:755\u2013773","journal-title":"Pflugers Arch"},{"key":"629_CR82","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","volume":"383","author":"S Palfi","year":"2014","unstructured":"Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugieres P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA (2014) Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1\/2 trial. Lancet 383:1138\u20131146","journal-title":"Lancet"},{"key":"629_CR83","doi-asserted-by":"crossref","unstructured":"Paolini Sguazzi G, Muto V, Tartaglia M, Bertini E, Compagnucci C (2021) Induced pluripotent stem cells (iPSCs) and gene therapy: a new era for the treatment of neurological diseases. Int J Mol Sci 22","DOI":"10.3390\/ijms222413674"},{"key":"629_CR84","doi-asserted-by":"crossref","first-page":"591","DOI":"10.7326\/M19-2534","volume":"172","author":"Parkinson Study Group STEADY-PD III Investigators","year":"2020","unstructured":"Parkinson Study Group STEADY-PD III Investigators (2020) Isradipine versus placebo in early Parkinson disease: a randomized trial. Ann Intern Med 172:591\u2013598","journal-title":"Ann Intern Med"},{"key":"629_CR85","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1021\/acschemneuro.0c00309","volume":"11","author":"J Parres-Gold","year":"2020","unstructured":"Parres-Gold J, Chieng A, Wong Su S, Wang Y (2020) Real-time characterization of cell membrane disruption by alpha-synuclein oligomers in live SH-SY5Y neuroblastoma cells. ACS Chem Nerosci 11:2528\u20132534","journal-title":"ACS Chem Nerosci"},{"key":"629_CR86","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.biopsych.2014.11.020","volume":"77","author":"A Pinggera","year":"2015","unstructured":"Pinggera A, Lieb A, Benedetti B, Lampert M, Monteleone S, Liedl KR, Tuluc P, Striessnig J (2015) CACNA1D de novo mutations in autism spectrum disorders activate Cav1.3 L-type calcium channels. Biol Psychiatry 77:816\u2013822","journal-title":"Biol Psychiatry"},{"key":"629_CR87","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0092-8674(00)00013-1","volume":"102","author":"J Platzer","year":"2000","unstructured":"Platzer J, Engel J, Schrott-Fischer A, Stephan K, Bova S, Chen H, Zheng H, Striessnig J (2000) Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+ channels. Cell 102:89\u201397","journal-title":"Cell"},{"key":"629_CR88","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/mds.26078","volume":"30","author":"W Poewe","year":"2015","unstructured":"Poewe W, Antonini A (2015) Novel formulations and modes of delivery of levodopa. Mov Disord 30:114\u2013120","journal-title":"Mov Disord"},{"key":"629_CR89","doi-asserted-by":"crossref","unstructured":"Rahman MU, Bilal M, Shah JA, Kaushik A, Teissedre PL, Kujawska M (2022) CRISPR-Cas9-based technology and its relevance to gene editing in Parkinson's disease. Pharmaceutics 14","DOI":"10.3390\/pharmaceutics14061252"},{"key":"629_CR90","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.parkreldis.2022.01.022","volume":"96","author":"O Rascol","year":"2022","unstructured":"Rascol O, Tonges L, deVries T, Jaros M, Quartel A, Jacobs D, ALLAY-LID I and ALLAY-LID II Study Groups (2022) Immediate-release\/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: analysis of the randomized, controlled ALLAY-LID studies. Parkinsonism Relat Disord 96:65\u201373","journal-title":"Parkinsonism Relat Disord"},{"key":"629_CR91","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrn2915","volume":"11","author":"P Redgrave","year":"2010","unstructured":"Redgrave P, Rodriguez M, Smith Y, Rodriguez-Oroz MC, Lehericy S, Bergman H, Agid Y, DeLong MR, Obeso JA (2010) Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat Rev Neurosci 11:760\u2013772","journal-title":"Nat Rev Neurosci"},{"key":"629_CR92","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.biopsych.2016.07.012","volume":"81","author":"IA Romme","year":"2017","unstructured":"Romme IA, de Reus MA, Ophoff RA, Kahn RS, van den Heuvel MP (2017) Connectome disconnectivity and cortical gene expression in patients with schizophrenia. Biol Psychiatry 81:495\u2013502","journal-title":"Biol Psychiatry"},{"key":"629_CR93","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci O, McCague S, Cross D, Marshall KA, Walshire J, Kehoe TL, Reichert H, Davis M, Raffini L, George LA, Hudson FP, Dingfield L, Zhu X, Haller JA, Sohn EH, Mahajan VB, Pfeifer W, Weckmann M, Johnson C, Gewaily D, Drack A, Stone E, Wachtel K, Simonelli F, Leroy BP, Wright JF, High KA, Maguire AM (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390:849\u2013860","journal-title":"Lancet"},{"key":"629_CR94","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1089\/104303400750035726","volume":"11","author":"AM Sandmair","year":"2000","unstructured":"Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, Tyynela K, Turunen M, Vanninen R, Lehtolainen P, Paljarvi L, Johansson R, Vapalahti M, Yla-Herttuala S (2000) Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 11:2197\u20132205","journal-title":"Hum Gene Ther"},{"key":"629_CR95","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.3233\/JPD-212679","volume":"11","author":"IM Sandoval","year":"2021","unstructured":"Sandoval IM, Marmion DJ, Meyers KT, Manfredsson FP (2021) Gene therapy to modulate alpha-synuclein in synucleinopathies. J Parkinsons Dis 11:S189\u2013S197","journal-title":"J Parkinsons Dis"},{"key":"629_CR96","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.nurx.2006.08.001","volume":"3","author":"T Schallert","year":"2006","unstructured":"Schallert T (2006) Behavioral tests for preclinical intervention assessment. NeuroRx 3:497\u2013504","journal-title":"NeuroRx"},{"key":"629_CR97","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.biopsych.2008.09.008","volume":"65","author":"S Schuster","year":"2009","unstructured":"Schuster S, Doudnikoff E, Rylander D, Berthet A, Aubert I, Ittrich C, Bloch B, Cenci MA, Surmeier DJ, Hengerer B, Bezard E (2009) Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry 65:518\u2013526","journal-title":"Biol Psychiatry"},{"key":"629_CR98","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40478-018-0653-7","volume":"7","author":"RC Sellnow","year":"2019","unstructured":"Sellnow RC, Newman JH, Chambers N, West AR, Steece-Collier K, Sandoval IM, Benskey MJ, Bishop C, Manfredsson FP (2019) Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia. Acta Neuropathol Commun 7:8","journal-title":"Acta Neuropathol Commun"},{"key":"629_CR99","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1124\/mol.108.049981","volume":"75","author":"MJ Sinnegger-Brauns","year":"2009","unstructured":"Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J (2009) Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol 75:407\u2013414","journal-title":"Mol Pharmacol"},{"key":"629_CR100","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1460-9568.2010.07077.x","volume":"31","author":"KE Soderstrom","year":"2010","unstructured":"Soderstrom KE, O'Malley JA, Levine ND, Sortwell CE, Collier TJ, Steece-Collier K (2010) Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats. Eur J Neurosci 31:478\u2013490","journal-title":"Eur J Neurosci"},{"key":"629_CR101","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/mds.27695","volume":"34","author":"K Steece-Collier","year":"2019","unstructured":"Steece-Collier K, Stancati JA, Collier NJ, Sandoval IM, Mercado NM, Sortwell CE, Collier TJ, Manfredsson FP (2019) Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia. Mov Disord 34:697\u2013707","journal-title":"Mov Disord"},{"key":"629_CR102","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1042\/BST0340903","volume":"34","author":"J Striessnig","year":"2006","unstructured":"Striessnig J, Koschak A, Sinnegger-Brauns MJ, Hetzenauer A, Nguyen NK, Busquet P, Pelster G, Singewald N (2006) Role of voltage-gated L-type Ca2+ channel isoforms for brain function. Biochem Soc Trans 34:903\u2013909","journal-title":"Biochem Soc Trans"},{"key":"629_CR103","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.biopsych.2013.05.006","volume":"75","author":"LM Suarez","year":"2014","unstructured":"Suarez LM, Solis O, Carames JM, Taravini IR, Solis JM, Murer MG, Moratalla R (2014) L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice. Biol Psychiatry 75:711\u2013722","journal-title":"Biol Psychiatry"},{"key":"629_CR104","doi-asserted-by":"crossref","first-page":"10736","DOI":"10.1074\/jbc.R112.410530","volume":"288","author":"DJ Surmeier","year":"2013","unstructured":"Surmeier DJ, Schumacker PT (2013) Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease. J Biol Chem 288:10736\u201310741","journal-title":"J Biol Chem"},{"key":"629_CR105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0896-6273(95)90294-5","volume":"14","author":"DJ Surmeier","year":"1995","unstructured":"Surmeier DJ, Bargas J, Hemmings HC Jr, Nairn AC, Greengard P (1995) Modulation of calcium currents by a D1 dopaminergic protein kinase\/phosphatase cascade in rat neostriatal neurons. Neuron 14:385\u2013397","journal-title":"Neuron"},{"key":"629_CR106","doi-asserted-by":"crossref","first-page":"a009290","DOI":"10.1101\/cshperspect.a009290","volume":"2","author":"DJ Surmeier","year":"2012","unstructured":"Surmeier DJ, Guzman JN, Sanchez J, Schumacker PT (2012) Physiological phenotype and vulnerability in Parkinson's disease. Cold Spring Harb Perspect Med 2:a009290","journal-title":"Cold Spring Harb Perspect Med"},{"key":"629_CR107","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.conb.2014.07.008","volume":"29","author":"DJ Surmeier","year":"2014","unstructured":"Surmeier DJ, Graves SM, Shen W (2014) Dopaminergic modulation of striatal networks in health and Parkinson's disease. Curr Opin Neurobiol 29:109\u2013117","journal-title":"Curr Opin Neurobiol"},{"key":"629_CR108","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.expneurol.2017.08.001","volume":"298","author":"DJ Surmeier","year":"2017","unstructured":"Surmeier DJ, Halliday GM, Simuni T (2017a) Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease. Exp Neurol 298:202\u2013209","journal-title":"Exp Neurol"},{"key":"629_CR109","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbrc.2016.08.168","volume":"483","author":"DJ Surmeier","year":"2017","unstructured":"Surmeier DJ, Schumacker PT, Guzman JD, Ilijic E, Yang B, Zampese E (2017b) Calcium and Parkinson's disease. Biochem Biophys Res Commun 483:1013\u20131019","journal-title":"Biochem Biophys Res Commun"},{"key":"629_CR110","first-page":"1","volume-title":"xPharm: the comprehensive pharmacology reference","author":"FH Sven Moosmang","year":"2009","unstructured":"Sven Moosmang FH (2009a) Cav1.1 voltage-gated calcium channel. In: Enna DBBSJ (ed) xPharm: the comprehensive pharmacology reference. Elsevier, pp 1\u20134"},{"key":"629_CR111","first-page":"1","volume-title":"xPharm: the comprehensive pharmacology reference","author":"FH Sven Moosmang","year":"2009","unstructured":"Sven Moosmang FH (2009b) Cav1.4 voltage-gated calcium channel. In: Enna DBBSJ (ed) xPharm: the comprehensive pharmacology reference. Elsevier, pp 1\u20137"},{"key":"629_CR112","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1016\/j.bbamem.2012.07.007","volume":"1818","author":"L Tosatto","year":"2012","unstructured":"Tosatto L, Andrighetti AO, Plotegher N, Antonini V, Tessari I, Ricci L, Bubacco L, Dalla Serra M (2012) Alpha-synuclein pore forming activity upon membrane association. Biochim Biophys Acta 1818:2876\u20132883","journal-title":"Biochim Biophys Acta"},{"key":"629_CR113","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/j.1742-4658.2012.08489.x","volume":"279","author":"IF Tsigelny","year":"2012","unstructured":"Tsigelny IF, Sharikov Y, Wrasidlo W, Gonzalez T, Desplats PA, Crews L, Spencer B, Masliah E (2012) Role of alpha-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS J 279:1000\u20131013","journal-title":"FEBS J"},{"issue":"3","key":"629_CR114","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/acn3.51300","volume":"8","author":"CS Venuto","year":"2021","unstructured":"Venuto CS, Yang L, Javidnia M, Oakes D, James Surmeier D, Simuni T (2021) Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease. Ann Clin Transl Neurol 8(3):603\u2013612","journal-title":"Ann Clin Transl Neurol"},{"issue":"14","key":"629_CR1000","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1021\/bi0121353","volume":"41","author":"MJ Volles","year":"2002","unstructured":"Volles MJ, Lansbury PT Jr (2002) Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson\u2019s disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41(14):4595\u20134602","journal-title":"Biochemistry"},{"key":"629_CR115","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.neuron.2013.05.014","volume":"79","author":"NR Wall","year":"2013","unstructured":"Wall NR, De La Parra M, Callaway EM, Kreitzer AC (2013) Differential innervation of direct- and indirect-pathway striatal projection neurons. Neuron 79:347\u2013360","journal-title":"Neuron"},{"key":"629_CR116","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/009885881003600202","volume":"36","author":"RF Wilson","year":"2010","unstructured":"Wilson RF (2010) The death of Jesse Gelsinger: new evidence of the influence of money and prestige in human research. Am J Law Med 36:295\u2013325","journal-title":"Am J Law Med"},{"key":"629_CR117","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/3-211-32234-5_1","volume":"31","author":"T Wirth","year":"2006","unstructured":"Wirth T, Yla-Herttuala S (2006) Gene technology based therapies in the brain. Adv Tech Stand Neurosurg 31:3\u201332","journal-title":"Adv Tech Stand Neurosurg"},{"key":"629_CR118","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.gene.2013.03.137","volume":"525","author":"T Wirth","year":"2013","unstructured":"Wirth T, Parker N, Yla-Herttuala S (2013) History of gene therapy. Gene 525:162\u2013169","journal-title":"Gene"},{"key":"629_CR119","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1523\/JNEUROSCI.21-16-05944.2001","volume":"21","author":"W Xu","year":"2001","unstructured":"Xu W, Lipscombe D (2001) Neuronal Ca(V)1.3alpha(1) L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines. J Neurosci Off J Soc Neurosci 21:5944\u20135951","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"629_CR120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-981-16-4254-8_5","volume":"1349","author":"SQZ Yeow","year":"2021","unstructured":"Yeow SQZ, Loh KWZ, Soong TW (2021) Calcium channel splice variants and their effects in brain and cardiovascular function. Adv Exp Med Biol 1349:67\u201386","journal-title":"Adv Exp Med Biol"},{"key":"629_CR121","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/pr.114.009654","volume":"67","author":"GW Zamponi","year":"2015","unstructured":"Zamponi GW, Striessnig J, Koschak A, Dolphin AC (2015) The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev 67:821\u2013870","journal-title":"Pharmacol Rev"},{"key":"629_CR122","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.conb.2017.08.004","volume":"48","author":"S Zhai","year":"2018","unstructured":"Zhai S, Tanimura A, Graves SM, Shen W, Surmeier DJ (2018) Striatal synapses, circuits, and Parkinson's disease. Curr Opin Neurobiol 48:9\u201316","journal-title":"Curr Opin Neurobiol"},{"key":"629_CR123","doi-asserted-by":"crossref","first-page":"11655","DOI":"10.1523\/JNEUROSCI.0288-13.2013","volume":"33","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Meredith GE, Mendoza-Elias N, Rademacher DJ, Tseng KY, Steece-Collier K (2013) Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses. J Neurosci Off J Soc Neurosci 33:11655\u201311667","journal-title":"J Neurosci Off J Soc Neurosci"}],"container-title":["Handbook of Experimental Pharmacology","Voltage-gated Ca2+ Channels: Pharmacology, Modulation and their Role in Human Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2022_629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T22:41:09Z","timestamp":1690843269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2022_629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9783031384363","9783031384370"],"references-count":123,"URL":"https:\/\/doi.org\/10.1007\/164_2022_629","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"3 January 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"We would like to acknowledge the assistance of Devon Eldred and Rachel Harmon for their contributions on researching literature on channelopathies (Eldred) and the gene therapy (Harmon) and providing information used in the writing of this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"KSC and MEC conceived and wrote the text, and designed and composed the figures. FPM has provided intellectual input to all studies discussed in this review and provided extensive editing of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}